Comparison of hospital costs in peripheral t-cell lymphoma patients treated with pralatrexate or romidepsin.

e18280Background: Peripheral T-Cell Lymphoma (PTCL) is a rare, aggressive form of non-hodgkin lymphoma. Initial treatment consists of conventional chemotherapy regimens; although novel therapies for relapsed/refractory patients are available there is a lack of information on real-world costs associated with these products. The objective of this study was to examine costs and healthcare resource use associated with two of these novel products, romidepsin and pralatrexate. Methods: A retrospective analysis examined costs in PTCL patients treated with pralatrexate- (n = 50) and romidepsin-based (n = 59) regimens in a nationally representative MedAssets hospital-based administrative claims dataset covering inpatient and outpatient services. Costs were collected during the time patients were considered to be on therapy and were standardized into cost per day. Between group differences were tested using analysis of variance and multivariable general linear regression Results: On average, pralatrexate patients h...